Caricamento...
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
Approximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid death. No vaccines or antiviral treatments have yet proven effective against COVID-19. Patients with severe COVID-19 experience elevated plasma...
Salvato in:
| Pubblicato in: | Clin Immunol |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
The Authors. Published by Elsevier Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7308779/ https://ncbi.nlm.nih.gov/pubmed/32585295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2020.108517 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|